{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=10", "query": { "intervention": "PCD", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 456, "total_pages": 46, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T20:56:12.998Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02879617", "title": "A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer NSCLC" ], "interventions": [ { "name": "durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Academic Thoracic Oncology Medical Investigators Consortium", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2017-04-04", "completion_date": "2022-06-04", "has_results": true, "last_update_posted_date": "2024-01-05", "last_synced_at": "2026-10-22T20:56:12.998Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Dallas, Texas", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02879617" }, { "nct_id": "NCT02569112", "title": "Evaluation of CoolSculpt Combining Venus Legacy Technology for Enhanced Results in Fat Reduction & Laxity of the Flanks", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adipose Tissue" ], "interventions": [ { "name": "multipolar RF, varipulse", "type": "DEVICE" }, { "name": "cryolipolysis", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Venus Concept", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "21 Years to 50 Years" }, "enrollment_count": 10, "start_date": "2015-08", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2018-06-18", "last_synced_at": "2026-10-22T20:56:12.998Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02569112" }, { "nct_id": "NCT04908254", "title": "A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphedema", "Lymphedema of Upper Arm", "Lymphedema, Breast Cancer" ], "interventions": [ { "name": "Crossover Device (PCD or Dayspring - alternate to first group)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Koya Medical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-06-01", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2025-12-09", "last_synced_at": "2026-10-22T20:56:12.998Z", "location_count": 2, "location_summary": "Los Altos, California • Morgan Hill, California", "locations": [ { "city": "Los Altos", "state": "California" }, { "city": "Morgan Hill", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04908254" }, { "nct_id": "NCT03256773", "title": "High Resolution Micro OCT Imaging", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis", "COPD", "PCD - Primary Ciliary Dyskinesia", "Covid19", "Sinusitis", "ILD", "Normal Controls" ], "interventions": [], "intervention_types": [], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 160, "start_date": "2016-04-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-22T20:56:12.998Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03256773" }, { "nct_id": "NCT05685186", "title": "A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Ciliary Dyskinesia" ], "interventions": [ { "name": "Spirometry", "type": "DIAGNOSTIC_TEST" }, { "name": "Multiple Breath Washout (MBW)", "type": "DIAGNOSTIC_TEST" }, { "name": "Mucociliary Clearance (MCC)", "type": "DIAGNOSTIC_TEST" }, { "name": "CT of the chest", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI of the chest", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "ReCode Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 31, "start_date": "2023-03-08", "completion_date": "2025-06-30", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-22T20:56:12.998Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05685186" }, { "nct_id": "NCT03820986", "title": "Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Placebo for lenvatinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 674, "start_date": "2019-03-12", "completion_date": "2024-11-01", "has_results": true, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-22T20:56:12.998Z", "location_count": 17, "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03820986" }, { "nct_id": "NCT03829332", "title": "Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Placebo for lenvatinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 623, "start_date": "2019-03-13", "completion_date": "2024-04-24", "has_results": true, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-10-22T20:56:12.998Z", "location_count": 18, "location_summary": "Anchorage, Alaska • Chandler, Arizona • Bakersfield, California + 15 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03829332" }, { "nct_id": "NCT05338775", "title": "A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/ Refractory Multiple Myeloma" ], "interventions": [ { "name": "Talquetamab", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "PD-1 Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2022-05-25", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-22T20:56:12.998Z", "location_count": 7, "location_summary": "Denver, Colorado • New York, New York • Winston-Salem, North Carolina + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05338775" }, { "nct_id": "NCT03664024", "title": "Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2018-10-30", "completion_date": "2021-11-05", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-10-22T20:56:12.998Z", "location_count": 3, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03664024" }, { "nct_id": "NCT05533697", "title": "Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "mRNA-4359", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 361, "start_date": "2022-09-01", "completion_date": "2032-02-18", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-22T20:56:12.998Z", "location_count": 16, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05533697" } ] }